|
CN101848735A
|
|
Novel neurturin conjugates for pharmaceutical use
|
|
WO2008015023A2
|
|
Use of photomedin products for preventing and/or treating neuronal dysfunctions
|
|
CN101466716A
|
|
Thienopyrimidines having MNKL/MNK2 inhibiting activity for pharmaceutical compositions
|
|
WO2007059905A2
|
|
Thienopyrimidines treating inflammatory diseases
|
|
EP1889847A1
|
|
Pyrrolopyrimidines for pharmaceutical compositions
|
|
EP1872790A1
|
|
New formulation for increasing bioavailability of neurturin
|
|
WO2006136402A1
|
|
Thienopyrimidines for pharmaceutical compositions
|
|
WO2006136374A2
|
|
Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells
|
|
EP1879591A1
|
|
Use of azapaullones for preventing and treating pancreatic autoimmune disorders
|
|
EP1885454A2
|
|
Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
|
|
WO2006108651A2
|
|
Use of activin products for preventing and treating diabetes and/or metabolic syndrome
|
|
WO2006013114A1
|
|
Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
|
EP1728873A1
|
|
Use of an insulinoma cell for identifying pancreatic beta-cell mitogens
|
|
EP2096120A2
|
|
Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
|
EP1706134A2
|
|
Use of protein products for preventing and treating pancreatic diseases and/or obestiy and/or metabolic syndrome
|
|
WO2005067957A2
|
|
Use of a dg147 protein product for preventing and treating metabolic disorders
|
|
EP1746099A1
|
|
Mnk1 or Mnk2 inhibitors
|
|
US2007110728A1
|
|
Method for preventing and treating diabetes using dg119
|
|
US2005222070A1
|
|
Pancreas-specific proteins
|
|
EP1694354A1
|
|
Method for preventing and treating diabetes using neurturin
|
